Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 1
2004 1
2005 1
2006 5
2007 1
2008 2
2013 1
2014 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, Robinson S, Luke KH, Wu JK, Gill K, Lillicrap D, Babyn P, McLimont M, Blanchette VS; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Feldman BM, et al. J Thromb Haemost. 2006 Jun;4(6):1228-36. doi: 10.1111/j.1538-7836.2006.01953.x. J Thromb Haemost. 2006. PMID: 16706965 Free article. Clinical Trial.
A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M, Lillicrap D, Rivard GE, Teitel J, Carcao M, Hensman C, Walker I; Association of Hemophilia Clinic Directors of Canada. Rubinger M, et al. Haemophilia. 2008 Mar;14(2):281-6. doi: 10.1111/j.1365-2516.2007.01634.x. Epub 2008 Jan 8. Haemophilia. 2008. PMID: 18194308
A survey of factor prophylaxis in the Canadian haemophilia A population.
Blanchette P, Rivard G, Israels S, Robinson S, Ali K, Walker I, Stain AM, Blanchette V; Association of Hemophilia Clinic Directors of Canada and Canadian Association of Nurses in Hemophilia Care. Blanchette P, et al. Haemophilia. 2004 Nov;10(6):679-83. doi: 10.1111/j.1365-2516.2004.01045.x. Haemophilia. 2004. PMID: 15569161
Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.
O'Brien LA, James PD, Othman M, Berber E, Cameron C, Notley CR, Hegadorn CA, Sutherland JJ, Hough C, Rivard GE, O'Shaunessey D, Lillicrap D; Association of Hemophilia Clinic Directors of Canada. O'Brien LA, et al. Blood. 2003 Jul 15;102(2):549-57. doi: 10.1182/blood-2002-12-3693. Epub 2003 Mar 20. Blood. 2003. PMID: 12649144 Free article.
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
Carcao M, St Louis J, Poon MC, Grunebaum E, Lacroix S, Stain AM, Blanchette VS, Rivard GE; Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada. Carcao M, et al. Haemophilia. 2006 Jan;12(1):7-18. doi: 10.1111/j.1365-2516.2005.01170.x. Haemophilia. 2006. PMID: 16409170
15 results